Riverhead Capital: Value Co-Creation with 90% of Portfolio Companies Achieving IPO or Follow-on Financing

Since the beginning of this year, key policy documents issued by the central government have frequently highlighted the need to “expand patient capital,” emphasizing its critical role in original and pioneering technological innovation. Due to their large scale, long investment horizons, and stable funding sources, insurance funds have emerged as a representative form of patient capital, playing an increasingly important role in serving national strategies, supporting the real economy, and safeguarding national welfare and people’s livelihoods. The introduction of the concept of patient capital has also broadened the investment scope for insurance funds, further enhancing the capacity of financial services to support new quality productive forces.

As a pioneer in insurance-backed funds, Sunshine Ronghui Capital was established in 2015. It is among the first batch of private insurance fund managers approved by the National Financial Regulatory Administration (formerly the China Banking and Insurance Regulatory Commission) and has long been regarded as an “honor student” of patient capital.

Sunshine Ronghui Capital, guided by the principle of co-creating value, adopts a top-down investment strategy across the two major sectors of healthcare and emerging technologies, “adhering to the selection of the best among the best.”, has invested in numerous star projects including Mindray Medical, Tongyuankang Pharma, Huzhou Shenke, Yingsheng Biotech, Silicon-Based Bionics, Raykol Group, Kunshan Yiyuan, Guanhuai Medical, Saipu Biotech, and Huaxin Medical. Over the past decade, among the more than 100 projects invested in by Sunshine Ronghui Capital, it has accompanied 90% of its portfolio companies through IPOs or new rounds of financing.

When asked by VCBeat,Mr. Shi Shenghao, Managing Partner of Sunshine Ronghui CapitalWhen asked about the secret behind such an impressive track record, concepts like “prudence and professionalism” and “industry-oriented thinking” were frequently mentioned. Building on these keywords, VCBeat seeks to outline the underlying logic of Sunshine Ronghui Capital as a patient capital firm that creates value through investment, offering insights for industry reference.

From a macro perspective, China’s healthcare and emerging technology sectors are in a phase of rapid growth, an economic environment that is often accompanied by significant market volatility. As an investment firm backed by insurance capital, Sunshine Ronghui Capital adopts a more stable and prudent investment style.

Prior to making investment decisions, Sunshine Ronghui Capital regards industry research as the primary gateway to value investing. By conducting in-depth industry research within specific sub-sectors and mapping out industry landscapes, the firm gains a comprehensive understanding of industry dynamics, market size, future trends, and key drivers. This approach enables the identification of high-potential investment opportunities while avoiding blind or herd-like investments.

This investment approach rigorously tests the investment team’s “industry mindset,” requiring not only a comprehensive understanding of the industry as a whole, each segment of the value chain, and the interrelationships among different sectors, but also cross-disciplinary capabilities in technology and finance, as well as deep professional expertise and an extensive network of industry connections.

At this juncture, Sunshine Ronghui Capital exudes strong confidence. Mr. Shi Shenghao, Managing Partner of Sunshine Ronghui Capital, steers the firm’s investment direction, drawing on his 30 years of experience in healthcare operations, investment, and management. The firm’s investment team also boasts extensive industry expertise, with the core team averaging over 10 years of experience. Furthermore, Sunshine Ronghui Capital has segmented its investment team by specialized fields to enable full leverage of their respective resource networks within these domains. This approach fosters a robust think-tank effect, providing timely and accurate information support for investment decisions, thereby ensuring their scientific rigor and precision.

The “top-down” investment approach, combined with a team built on “universal industry backgrounds,” has invisibly established the core investment capabilities of Sunshine Ronghui Capital.For a fund, this also signifies robust deal-sourcing capabilities, ensuring the early and rapid identification of high-potential projects.

This also explains why Sunshine Ronghui Capital invested during the Series A financing rounds of a number of well-known enterprises, including Rayco Group, Kunshan Yiyuan, Guanhuai Medical, Saipu Biology, Huaxin Biology, and Tongyuankang Pharmaceutical, which recently listed on the Hong Kong Stock Exchange. Notably, Sunshine Ronghui Capital served as the lead investor or sole investor in most of these projects. It is evident that providing end-to-end support and increasing investment across multiple rounds are hallmark features of Sunshine Ronghui Capital’s investment strategy.

Sunshine Ronghui Capital, an institution originally focused on mid-to-late-stage project investments, has boldly shifted its investment strategy to engage in early-stage and small-scale investments. This confidence stems from its unique and efficient risk control culture system. For instance, the investment team adheres to the iron rule of exhausting all aspects of a project before making any move; projects undergo rigorous screening and thorough market research; risk control personnel also participate in due diligence alongside the investment team, being involved throughout the pre-investment, during-investment, and post-investment stages.

Mr. Shi Shenghao cited examples to illustrate that, due to changes in the international landscape, many of China’s technological sectors remain constrained by foreign technical blockades and “chokepoint” restrictions, preventing full autonomy and controllability. This has posed significant challenges to the security and integrity of China’s supply chains. As a foundational element of technological advancement and an upstream component of numerous industrial chains, scientific research instruments and equipment hold substantial significance for national scientific and technological progress, supply chain security, and the development of new-quality productive forces.

It was precisely by focusing on the development of domestically produced scientific research instruments and the growing demand for laboratory automation upgrades that Sunshine Ronghui Capital identified Reeko Group, a company that has been deeply engaged in this field for over a decade and has established a comprehensive product portfolio. Consequently, in 2022, Sunshine Ronghui Capital, as the lead investor, facilitated Reeko Group’s completion of its first round of financing, which exceeded RMB 100 million.

Laboratory automation is a comprehensive system that requires deep integration of multidisciplinary knowledge, technologies, and innovative thinking, with high professional barriers. How did Sunshine Ronghui Capital “select the best of the best” in choosing Reeko Group? We spoke with Mr. Shi Shenghao andMr. Lin Zhijie, Founder of Raykol Groupin cross-interviews.

Possessing technological barriers is a key criterion for Sunshine Ronghui Capital when screening innovative projects.Even in highly competitive markets with relatively mature technologies, companies that leverage their long-term technological accumulation and continuous process optimization to produce products that are both excellent in quality and price-competitive can still attract the attention and favor of capital.

Over the past decade, Raykol Group has closely followed the trend of domestic substitution for scientific research instruments in China, achieving a three-stage leap from independently developing single-unit automation modules to expanding into diverse sample preparation equipment, and finally laying out its presence in life science automation. The company has established a “pyramid” business structure ranging from single-unit automation to multi-functional platform automation and smart laboratories, along with a business matrix covering hardware, software, consumables/reagents, and testing services, providing end-to-end automated and intelligent solutions for the life sciences industry.

Technological innovation is also a key criterion for Sunshine Ronghui Capital in evaluating innovative projects.If a company can achieve technological firsts or reach a leading position in the international market, it will significantly enhance its market appeal and bargaining power. Raykol boasts an expert team that pioneered the development of automated sample preparation in China, with its core members possessing over 20 years of experience in physicochemical analysis and laboratory automation, thereby providing the Raykol Group with sustained technological innovation capabilities. In 2018, the Raykol Group established a Research Institute to conduct scientific research and technological innovation through building its own R&D team, collaborating with external academicians and experts, and integrating industry, academia, and research efforts.

Mr. Lin Zhijie shared that, given the unique nature of laboratory environments, there is a strong inertia in customer selection for laboratory automation. During procurement, customers tend to favor tool products with high brand recognition and positive market reputation, and once a supplier is selected, they are unlikely to switch easily. Benefiting from over a decade of accumulation, Raykol Group now serves more than 3,000 clients, with nearly 5,000 installed systems, earning widespread acclaim from its customers.

Mr. Shi Shenghao added that the Raykol team has conducted extensive exploration and trial-and-error based on continuous customer feedback, gradually improving product quality to a level comparable with imported products, while offering better cost-effectiveness.

This pursuit of ultimate craftsmanship and innovative technology not only demonstrates the company’s profound patience and robust strength, but also aligns withThe core values cherished by Sunshine Huihui Capital—prioritizing and investing in enterprises of new-quality productive forces that are characterized by high-quality standards, high-efficiency operations, and high technological content.

Applying this screening criterion reveals that a number of portfolio companies backed by Sunshine Fusion Capital—including Kunshan Yiyuan, a domestic unicorn in CT X-ray tubes; Care Medical, a leading platform enterprise in membrane science; Saipu Biology, a leading Chinese manufacturer of high-end biological consumables; and Qitan Technology, a pioneer in domestic nanopore sequencing technology—often possess significant process-related barriers to entry and technological innovativeness.

Sunshine Ronghui Capital’s investment philosophy extends beyond merely identifying high-potential projects and enterprises; it is dedicated to empowering portfolio companies through post-investment support, thereby facilitating their sustainable development and maximizing value creation.

In post-investment management, Sunshine HuiRong Capital not only focuses on the financial health and capital operations of enterprises but also directs its attention to the cultivation and enhancement of new quality productive forces. For instance, it assists portfolio companies in laying out their upstream and downstream industrial chains, identifies top-tier talent from a strategic perspective, helps expand sales channels, and empowers these companies post-investment by leveraging its own industrial and financial resources. Meanwhile, through continuous investment, Sunshine HuiRong Capital is building an innovation ecosystem chain to form a complete innovation ecosystem, thereby accelerating the growth of new quality productive forces and supporting enterprises in achieving high-quality development.

Regarding the empowerment provided by Sunshine Ronghui Capital, Mr. Lin Zhijie of Ruike noted that the infusion of capital has significantly accelerated the implementation of multiple collaborative projects within the company. Furthermore, through capital platform activities, it has facilitated direct dialogue and cooperation with upstream and downstream players in the industry chain as well as closely related enterprises, thereby achieving effective alignment between technology and market demands.

Furthermore, Tianuo Maibo, Kerui Biology, Ningkang Ruizhu, and Borui Chuanghe are all representative enterprises that have benefited from the post-investment services provided by Sunshine Huihui Capital. Following its investments, Sunshine Huihui Capital has been deeply involved in the companies’ R&D and management operations, delivering substantial value-added services in areas such as technological iteration, product portfolio strategy, industrial collaboration, and talent development.

The core essence of patient capital lies in “a long-term perspective, value co-creation, and steady commitment,” which precisely aligns with the investment philosophy consistently upheld by Sunshine Ronghui Capital. This is evident from investment cases such as that of Ruike Group.Sunshine Ronghui Capital’s understanding and practice of “patient capital” are reflected in its rigorous approach to target selection, keen foresight regarding potential risks, close collaboration with founders and management teams, and proactive efforts to seek solutions. In essence, Sunshine Ronghui Capital acts less as a mere investor and more as a strategic partner that supports and accompanies companies throughout their growth journey.

Patient capital, as a form of capital that emphasizes long-term investment and stable returns, has gained widespread recognition in the capital markets for its importance. However, it still faces challenges in practice, such as investment philosophies driven by short-term interests, as well as the complexity and uncertainty of financial markets. These challenges require investors to possess higher risk management capabilities and investment wisdom.

In response, Mr. Shi Shenghao stated that the main theme of China’s venture capital environment has shifted from business model innovation to technological innovation, heralding the arrival of a new era defined by technological advancement. As investors, it is essential to align with the fundamental laws of industrial development, maintain steady and professional investment principles amidst cyclical fluctuations, and focus on acquiring high-quality assets characterized by growth potential, innovativeness, and supply chain barriers. Investors should remain committed to supporting the growth of these assets while minimizing external distractions.